Posted Sep 30, 2022, 4:45 PM
The opportunity was great for AdhexPharma, whose headquarters and production site are located in Chenôve, in the metropolis of Dijon (Côte-d’Or). Approached by the German group Tesa, which wanted to separate from its pharmaceutical division, the French manufacturer of transdermal patches, oral films and other continuous delivery drug delivery systems has just formalized the takeover of Tesla Labtec.
Based in Langenfeld and Hamburg, Germany, Tesa Labtec brings with it its German and Swiss customers. A major asset in the pharmaceutical sector. In 2021, AdhexPharma had already taken over the Bavarian activity and the associated patents from its competitor AMW. The newcomer also manufactures patches and oral films, but it entered this niche market through R&D, while AdhexPharma did the opposite.
Founded in 2007 to develop Solvay’s transdermal patch activity in France, the company started out as a manufacturer of hormonal, nicotine or anesthetic patches for large laboratories (Biogaran, Pierre Fabre), before setting up its own formulation unit in 2021. But with his thirty years of experience, Tesla Labtec will save him precious time and bring him on a platter his expertise in controlled substances, such as opioid painkillers.
Sixteen projects
“Tesla Labtec is very competitive on the oral film which dissolves in the mouth without the addition of water to deliver different types of drugs such as emergency drugs”, confirms Bruno Loiseau, CEO of AdhexPharma. The Burgundy SME employs 130 people today and is the only player in this niche market in France. A subsidiary of the French industrial holding Burgundy Ventures, it has invested 20 million euros since 2014 and has since experienced growth of 40% per year, which has raised its turnover to 29 million in 2021.
By taking over Tesla Labtec (80 employees and 15 million euros in turnover), it also offers itself a production capacity of 12 million products per year, which will be added to its own, 80 million. Between them, they have sixteen projects under development in a growing market, with prospects for the treatment of Alzheimer’s disease.
What benchmarks in a constantly changing world?
Political uncertainties, scientific innovations, war in Ukraine, energy and ecological transition… How to understand these changes? How to position yourself? Every day, the 200 journalists from the “Echos” editorial staff help you decipher economic, political and international news through surveys, analyses, press reviews, chronicles and editorials. Our subscribers know that they can rely on these resources to better navigate our complex environment and make the best strategic decisions.
